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Aminobisphosphonates are used for the treatment of benign and malignant bone disorders. As inhibitors of
the mevalonate pathway they exert direct anti-tumor effects in vitro and in preclinical models of bone
metastases. Bisphosphonates are thought to have an anti-angiogenic activity as decreased levels of VEGF have
been reported in some, although not all patients, following treatment with bisphosphonates. Direct effects of
bisphosphonates on tumor derived VEGF have not been examined in detail. We therefore investigated VEGF
expression in breast cancer cell lines following mevalonate pathway inhibition. Treatment of cell lines with
increasing doses of zoledronic acid and atorvastatin resulted in increased levels of VEGF production. Similar
results were seenwith the geranylgeranyltransferase I inhibitor GGTI-298. The induction of VEGF was reversed
by the supplementation of geranylgeranyl pyrophosphate but not by farnesyl pyrophosphate indicating that
this effect is mediated by inhibited geranylgeranylation. Previous reports have reported decreased VEGF levels
in patients following BP treatment in vivo. We assessed VEGF levels in patients with non-metastatic breast
cancer following repeated treatment with zoledronic acid. In contrast to our in vitro ﬁndings, VEGF serum
levels decreased in all patients after 6–9 months of treatment (by an average of 41%) as assessed in a small
pilot trial. These results indicate that tissues other than breast tumors contribute to the serum pool of
circulating VEGF andmay be responsible for the observed VEGF decreases. The increases of VEGF in the cancer
cells may provide a rationale for the combined treatment with VEGF inhibitors.
& 2013 Elsevier GmbH. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The occurrence of osteolytic lesions remains a feared long term
complication in patients with breast cancer. Amino-bisphosphonates
(BP) are a class of antiresorptive agents approved for the treatment of
metastatic bone disease [1,2]. BP act via inhibition of the FPP-
synthase, which is a key enzyme of the mevalonate pathway [3].
Aside from their potent antiresorptive properties, BP have been
associated with a direct antitumor potential. In vitro, BP induce
apoptosis and decrease proliferation and invasion of tumor cells [4].
While these results were conﬁrmed in a number of preclinical in vivo
models, results from two large clinical trials have yielded varying
results regarding the adjuvant use of zoledronic acid in breast cancer
patients [5,6]. One trial showed a signiﬁcant reduction in the risk of
disease progression in patients receiving zoledronic acid in addition. This is an open access article und
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den.de (T.D. Rachner).to endocrine therapy compared to endocrine therapy alone in
hormone-responsive breast cancer [5]. The other trial assessed the
response of breast cancer patients with different hormone receptor
expression and menopausal status to zoledronic acid in addition to
their standard adjuvant treatment. This study failed to provide
evidence to support the routine use of zoledronic acid in the
adjuvant management of breast cancer [6]. One of the proposed
antitumor effects of BP is their anti-angiogenic potential. A number of
studies have shown that serum levels of VEGF decrease in tumor
patients following treatment with bisphosphonates [7,8]. In one case,
serum concentrations of VEGF were shown to be suppressed as early
as 7 days after the ﬁrst infusion of zoledronic acid and remained
suppressed for the duration of the study, 84 days after the ﬁrst
infusion [7]. The ﬁnding of anti-angiogenic effects of these agents
was further supported by the ﬁnding that bisphosphonates inhibited
tumor vascularization in murine models of prostate carcinoma,
melanoma and myeloma [9–11]. However, these results could not
be conﬁrmed in all studies and in some studies VEGF levels remained
unaffected [12]. The molecular mechanisms responsible for these
effects have not been looked at in detail. It remains unclear, if the
observed regulation on VEGF is mediated via direct effects on cancer
cells or by effects on other cells such as macrophages or
endothelial cells.er the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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mevalonate pathway inhibition using zoledronic acid, atorvastatin
and speciﬁc inhibitors of farnesylation and geranylgeranylation in
breast cancer cell lines with different metastatic properties and
hormone receptor status.2. Materials and methods
2.1. Cells and reagents
Human breast cancer cells were purchased from ATCC (Mana-
ssas, VA), except for the bone seeking MDA-MET cells (subclones
of MDA-231 cells) which were a gift of Prof. L. Suva (Arkansas,
USA). All cell lines were cultured in DMEM/Ham's F-12 (PAA,
Pasching, Austria) with 10% fetal calf serum supreme (Lonza,
Cologne, Germany) and 1% penicillin/streptomycin (PAA, Pasching,
Austria). Cell line authenticity was determined by short tandem
repeat proﬁling and by matching with the known proﬁles at DSMZ
(German Collection of Microorganisms and Cell Culturs). Zoledro-
nic acid, atorvastatin, mevalonate, geranylgeranyl-pyrophosphate
(GGPP), farnesyl pyrophosphate (FPP), GGTI-298 and FTI-277 were
obtained from Sigma-Aldrich (Munich, Germany). Zoledronic acid
was solved in PBS. Mevalonate, FPP and GGPP were dissolved in
methanol:NH4OH solution and atorvastatin was dissolved in
DMSO. Appropriate controls were added to untreated control cells.
2.2. Cell culture and treatment
Breast cancer cell lines were treated with zoledronic acid
(100 mM), atorvastatin (10 mM), FTI-277 (0.01, 0.1, 1 mM) and
GGTI-298 (1, 5, 10 mM) for 24 h (unless otherwise indicated).
Mevalonate substrates (GGPP, FPP and mevalonate) were supple-
mented together with atorvastatin and zoledronic acid at concen-
trations shown to reverse speciﬁc pathway inhibition.
2.3. RNA isolation, RT and real-time PCR
RNA from the cell lines was isolated using the HighPure RNA
extraction kit from Roche according to the manufacturer's protocol.
500 ng RNA were reverse transcribed using Superscript II (Invitro-
gen, Darmstadt, Germany) and used for SYBR green-based real-time
PCR reactions using a standard protocol (Applied Biosystems).
Primer sequences for VEGFA were sense: GTGATGATTCTGCCCTCCTC
and anti-sense: CCTTGCTGCTCTACCTCCAC; for GAPDH sense: CAT-
CACCATCTTCCAGGAGCG and anti-sense: TGACCTTGCCCACA-
GCCTTG. PCR conditions were 50 1C for 2 min and 95 1C for
10 min followed by 40 cycles with 95 1C for 15 s and 60 1C for
1 min. The melting curve as assessed in the following program:
95 1C for 15 s, 60 1C for 1 min and 95 1C for 30 s. The results were
calculated applying the ΔΔCT method and are presented as relative
expression to the house keeping gene (GAPDH) or as a percentage
of control.
2.4. VEGF ELISA
VEGF ELISA was purchased from Thermo scientiﬁc (Waltham,
MA) and conducted as proposed by the manufacturer. Brieﬂy, cell
culture supernatants were diluted 1:5 (as predeﬁned by testing),
serum samples were used undiluted. Samples were assayed in
duplicates. 50 ml standard diluent was given to all wells and 50 ml
of samples and diluted standards were pipetted to the appropriate
wells and incubated for 2 h. Plates were washed and 100 ml of
biotinylated Antibody Reagent was added to all wells, after which
wells were incubated for another hour. After washing 100 ml of
prepared Streptavidin–HRP Solution was given to all wells,incubated for an hour and washed thrice. Then 100 ml of TMB
substrate solution was pipetted into all wells and after 30 min of
incubation the reaction was stopped and wells were measured and
values were calculated as proposed.
2.5. Western blot
Western blot analyses were performed as previously described
[13]. Brieﬂy, cells were washed and scraped in a lysis buffer and
quantiﬁed. 20 mg of protein were loaded on a SDS–PAGE and
transferred onto a 0.2 mm nitrocellulose membrane. After blocking
for 1 h with 5% non-fat dry milk in Tris-buffered saline with 1%
tween-20 (TBS-T), membranes were incubated with a primary
antibody overnight. After washing, the membrane was incubated
for 1 h with the HRP-conjugated secondary antibody. Membranes
were washed 3 times with TBS-T again, and proteins were
visualized with Super Signal (Pierce, Bonn, Germany) enhanced
chemiluminescence. Antibody for RAP1A (sc-1482) was from Santa
Cruz (Heidelberg, Germany) and the RAS (610001) antibody was
from BD Biosciences (Heidelberg, Germany).
2.6. Serum samples
Serum samples of patients were obtained after informed consent
and IRB approval. Patients with hormone receptor-negative, non-
metastatic breast cancer were treated with infusions of 4 mg zole-
dronic acid every threemonths. All patients received 1000mg Calcium
and 1000 IE Vitamin D per day for the duration of the study. None of
the patients receives any additional concomitant drugs known to
inﬂuence bone turnover. None of the patients sustained a fracture
during the study period nor were any other anti-resorptives given.
Control serum was taken before the ﬁrst administration of zoledronic
acid and before each further administration. All serum samples were
collected after an overnight fasting at the same time in the morning.
Blood samples were immediately worked up and stored at −80 1C
until the analyses were performed.
2.7. Statistical analyses
Results are presented as means7standard deviation (SD). All
experiments were repeated at least three times. Statistical evalua-
tions were performed using a one-way ANOVA or a Student´s
T-test. P valueso0.05 were considered statistically signiﬁcant.3. Results
3.1. Zoledronic acid and atorvastatin increase VEGF expression in
breast cancer
Three different breast cancer cell lines were treated with
100 mM zoledronic acid for 24 h and assessed for VEGF expression.
Base line expression of VEGF varied greatly between the different
cell lines. The hormone receptor positive MCF-7 cells had con-
siderably lower levels of VEGF compared to MDA-231 and their
metastatic subclones (data not shown). This is line with their
lower aggressiveness and lower metastatic properties. Following
exposure to zoledronic acid VEGF expression was signiﬁcantly up-
regulated in all three tested cell lines (MCF-7, MDA-231 and MDA-
MET) to 207%, 296% and 288% compared to PBS-treated cells,
respectively (Fig. 1A). To test whether this effect was mediated via
mevalonate pathway inhibition, the same cell lines were also
treated with 10 mM of atorvastatin. Atorvastatin increased VEGF
levels in all cell lines compared to control although the induction
was smaller in MDA-231 and MDA-MET cells than previously seen
with zoledronic acid (Fig. 1B). When treating MDA-231 cells for up
to 48 h, VEGF increases were seen as early as 6 h after treatment
with zoledronic acid and increased further after 24 h and 48 h
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Fig. 1. Zoledronic acid and atorvastatin increase VEGF expression in breast cancer cell lines. (A+B) Breast cancer cell lines (MCF-7, MDA-231 and MDA-MET) were treated
with zoledronic acid (100 mM) and atorvastatin (10 mM) for 24 h. Data are presented as the percentage expression relative to control treated (PBS, DMSO) cells, and are
mean7SD of 3 independent experiments. *Po0.05; **Po0.01.
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Fig. 2. Zoledronic acid and atorvastatin increase VEGF expression in breast cancer cell lines. (A+B) Treatment with zoledronic acid (100 mM) or atorvastatin (10 mM) for 6, 24,
and 48 h results in a time-dependent increase of VEGF expression in MDA-231 cells. Data are presented as the percentage expression relative to control treated (PBS, DMSO)
cells, and are mean7SD of 3 independent experiments. (C) Treatment of MDA-231 cells with zoledronic acid (100 mM) for 24 h increases VEGF protein in the cell
supernatant. Values are mean7SD of 3 independent experiments. **Po0.01.
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were ﬁrst noted after 24 h (Fig. 2B). Increased VEGF expression
also translated into higher levels of protein secretion as seen by an
increase from 1023.1764.4 pg/ml in control-treated cells to
1524.7785.8 pg/ml (+50%; Po0.01) in zoledronic acid treated
MDA-231 cells (Fig. 2C).
3.2. Induction of VEGF is mediated via inhibition of
geranylgeranylation
To further clarify the role of the mevalonate pathway in this
regulation, MDA-231 cells were treated with increasing concentrations
of FTI-277 and GGTI-298, which are speciﬁc inhibitors of farnesylation
and geranylgeranylation. We observed a dose-dependent increase of
VEGF expression after exposure to GGTI-298 (Po0.001), but no
signiﬁcant changes even in the highest concentrations of FTI-277
(Fig. 3A). Of note, the use of different concentrations of FTI-277 andGGTI-298 resulted from their different IC50 values. Relevant inhibition
of prenylation of RAP1A (geranylation) and RAS (farnesylation) was
veriﬁed by Western blot (Fig. 3B). When supplemented with GGPP
and FPP, only GGPP successfully reversed the effects of zoledronic acid
on VEGF expression. Supplementation of FPP had no signiﬁcant effect
on VEGF production. Together these data show that the VEGF increase
is regulated via inhibited geranylgeranylation (Fig. 4).
3.3. VEGF levels decrease in zoledronic acid treated patients in vivo
To see if these in vitro results could be conﬁrmed in vivo, we also
measured VEGF levels in patients with non-metastatic breast cancer at
base line and after 6 (or 9, if 6 months measurement was not
available) and 12 months. Base line levels of VEGF varied between
44.7 and 114.5 pg/ml. Following repeated treatment with zoledronic
acid VEGF levels decreased in all patients at 6 or 9 month measure-
ment, respectively (Fig. 5). Mean levels of VEGF decreased by 41%
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Fig. 3. VEGF expression is regulated by inhibited geranylgeranylation. (A) MDA-231 cells were treated with increasing concentrations of 1, 5 or 10 mM of GTI-298 (A) or 0.01,
0.1 or 1 mM of FTI-277 for 24 h. VEGF expression was assessed using qRT-PCR. Data are presented as the percentage expression relative to control treated (PBS, DMSO) cells,
and are mean7SD of 3 independent experiments. **Po0.01; ***Po0.001. (B) MDA-231 cells were treated with GTI-298 and FTI-277 as above. Assessment of unfarnesylated
RAS (upper band) and ungeranylated RAP1A conﬁrmed mevalonate pathway inhibition. Representative blots are shown. GAPDH is used as a loading control.
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Fig. 4. GGPP prevents VEGF induction by zoledronic acid. MDA-231 cells were
treated with either zoledronic acid (100 mM) alone or in combination with GGPP
(100 mM) or FPP (100 mM) and VEGF was assessed by qRT-PCR. Data are presented
as the percentage expression relative to control treated (PBS, DMSO) cells, and are
mean7SD of 3 independent experiments. *Po0.05; **Po0.01.
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Fig. 5. VEGF protein levels decrease in breast cancer patients treated with
zoledronic acid. Women with ER-negative non-metastatic disease were repeatedly
treated with zoledronic acid (4 mg) every 3 months. VEGF serum levels were
measured by ELISA at 6 (or 9 months) and 12 months.
T.D. Rachner et al. / Journal of Bone Oncology 2 (2013) 110–1154compared to baseline values. Of the 4 cases measured 12 months after
treatment was initiated, VEGF levels stayed supressed in 3 cases. In
one case VEGF levels normalized (98% of baseline value) at 12 months
after an initial suppression to 50% was observed after 9 months. No
patient had increased VEGF levels after treatment with
zoledronic acid.4. Discussion
This study investigated VEGF expression in breast cancer cells
following exposure to mevalonate inhibitors. An anti-angiogenic
potential of bisphosphonates is generally assumed as severalstudies have reported decreased serum VEGF levels in patients
following treatment with bisphosphonates [14]. This is line with
the decrease in serum VEGF levels observed in our pilot study.
Although the number of patients included in our study is too low
to draw conclusions, it underlines VEGF as a target of the
mevalonate pathway. Results from this study require validation
in larger trial. Unlike serum assessment of VEGF, direct effects of
BP on VEGF production by tumor cells has not been evaluated in
detail. Unexpectedly, we did not observe a decrease in breast
cancer-derived VEGF mRNA or protein levels following treatment
with zoledronic acid or atorvastatin. Instead, both agents resulted
in signiﬁcant increases of VEGF levels in all cell lines tested. It is
T.D. Rachner et al. / Journal of Bone Oncology 2 (2013) 110–115 5currently unclear which cell types are mainly responsible for the
commonly observed changes in serum VEGF following the treatment
of cancer patients with bisphosphonates. It is known that bispho-
sphonates have direct effects on endothelial cells by inhibiting pro-
liferation sensitizing them to TNF-induced cell death [15]. VEGF levels
have also been described to be supressed by zoledronic acid in
myeloma-associated macrophages, an effect that was enhanced by
co-treatment with the proteasome inhibitor bortezomib [16]. Little is
known about the direct effects of zoledronic acid tumor cells. In this
study, we show that different breast cancer cell lines increase VEGF
levels following exposure to bisphosphonates. However, concentra-
tions needed to achieve signiﬁcant effects on VEGF were high and
comparable to those previously shown to induce apoptosis and
growth inhibition [17]. The in vitro concentrations used in our
experiments exceeded those normally achievable in clinical routine.
While this limits the direct translational relevance of our study, it is
noteworthy that zoledronic acid, even when applied in low concen-
trations, did not suppress VEGF in breast cancer cells. To our knowl-
edge there are no data from animal studies indicating that zoledronic
acid increases angiogenesis following zoledronic treatment. However,
even when high doses of zoledronic acid are used in animal models,
these may still not reach the concentrations required to see effects
in vitro. VEGF not only induces vascularization but also acts as a direct
survival factor for tumor cells including breast cancer [18]. VEGF has
been shown to prevent radiation-induced apoptosis [19] and to up-
regulate Bcl-2 [20]. As the concentrations used in this study also
increased apoptosis, one explanation may be that the VEGF increase is
a result of increased cellular stress. This idea is supported by the
ﬁnding that VEGF levels were normalized when protein prenylation is
restored by supplementation of GGPP. As breast cancer VEGF levels
stay unchanged at low levels and increase with high concentrations of
zoledronic acid, our study provides some limited evidence that the
decreases in VEGF serum levels following BP exposure results from a
regulation of other cell types than the tumor cells.
A number of studies have shown that zoledronic acid has the
ability to potentiate effects of anti-tumor agents such as doxo-
rubicin [21] or everolimus [22]. In a recent paper the combination
of chemotherapy with a single infusion of 4 mg zoledronic acid in
patients with breast cancer was shown to result in a greater
suppression of VEGF levels at day 5 than with chemotherapy alone
[23]. The combination of an anti-angiogenic therapy with zole-
dronic acid may be an attractive option in some cases. However,
this therapy has been associated with an increased rate of
osteonecrosis of the jaw (ONJ) [24]. ONJ is a complication of
anti-resorptive therapy, while it is rarely seen when BP are given
for the treatment of osteoporosis, it is more common when given
in oncologic doses [25]. While the pathogenesis of ONJ remains
unclear, angiogenic suppression in osteoclasts following BP is one
proposed mechanism [26,27]. This hypothesis is supported by a
recent ﬁnding, that patients with highest suppression of VEGF
levels following BP administration were prone to ONJ [28].
In conclusion, we show that high doses of zoledronic acid may
increase VEGF expression in breast cancer cells via inhibited geranyl-
geranylation. While it is unlikely that tumor cells will be exposed to
these concentrations in the clinical setting, this study gives some
evidence that the observed decreases in serum VEGF following
bisphosphonate exposure is caused by cells other than breast
cancer cells.Role of the funding source
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